SGD Pharma charts ambitious growth strategy for 2024 following successful 2023 milestones

10 January 2024

SGD Pharma, a leading player in primary pharmaceutical glass packaging, has unveiled its ambitious roadmap aimed at securing global market leadership in the industry. CEO Olivier Rousseau outlined a comprehensive growth strategy spanning commercial, innovation, industrial, sustainability, HR, and M&A efforts for the year ahead.



Highlighting the groundwork laid in 2023, Rousseau emphasized pivotal investments that set the stage for SGD Pharma‘s forthcoming expansion. A notable milestone was the collaboration with Corning through a joint venture, backed by investment from Telangana state in India. This strategic alliance integrated Corning’s cutting-edge coating technology with SGD Pharma’s glass expertise, culminating in the production of Velocity Vials using Type I borosilicate glass tubing. The construction of a state-of-the-art tubing plant in Vemula, India, represents a significant step toward bolstering pharmaceutical packaging manufacturing and deploying Corning’s Velocity Vial technology across the region.

In tandem with its growth initiatives, SGD Pharma prioritized sustainability, attaining a gold EcoVadis sustainability rating and enhancing efforts in environmental consciousness, human rights, sustainable procurement, and ethical practices. The company’s CSR report outlined a three-pillar sustainability strategy focusing on decarbonization, sustainable compliance, and health and safety practices. Joining the Science Based Targets initiative underscored SGD Pharma’s commitment to aligning emissions reduction targets with global climate science, aiming for substantial reductions in CO2 emissions across its plants by 2030 and 2040.

Furthering its commitment to innovation, SGD Pharma introduced expansions to its product lines, including the Clareo range extension and the Sterinity range of ready-to-use vials, catering to diverse pharmaceutical needs. The unveiling of PROSEAL+ showcased the company’s dedication to preserving oral pharmaceutical products by providing robust hermetic seals.

Looking ahead, SGD Pharma’s CEO anticipates unveiling strategic developments for 2024, with Pharmapack 2024 set to witness significant announcements. The company’s investments in technology, sustainability, and product innovation affirm its unwavering commitment to driving the pharmaceutical glass packaging sector’s growth and innovation.

SGD Pharma’s pursuit of excellence and innovation positions it as a frontrunner in revolutionizing pharmaceutical glass packaging, promising a dynamic and impactful journey towards global market leadership.